Area under the curve in survival analyses has shown that the persistence of RANK-positive CTCs (positive ΔAUC) during denosumab administration was associated with a delay in time to bone metastasis and metastatic progression, but not in delayed visceral metastasis progression [43]. This evidence concerns the gene TNFRSF11A and bone metastasis.